(Z)-RG-13022  (Synonyms: (Z)-Tyrphostin RG13022)

(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor, which inhibits preferentially the TK activity of the EGF receptor and inhibits EGF-stimulated growth of cultured cells. (Z)-RG-13022 exerts an IC₅₀ of 11 μM for DNA synthesis in the HN5 cells, which is 3 times more potent than (E)-RG-13022 (IC₅₀=38 μM). (Z)-RG-13022 can be used for research of breast cancer cells^[1][2].

(Z)-RG-13022 (1-100 μM, 24 h) inhibits the DNA synthesis in the HN5 cells dose-dependently and doesn't affect the cell viability^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

266.29

C₁₆H₁₄N₂O₂

149286-90-8

N#C/C(C1=CN=CC=C1)=C\C2=CC(OC)=C(C=C2)OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Reddy KB, et al. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 1;52(13):3636-41.  [Content Brief]

  [2]. McLeod HL, et al. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer. 1996 Dec;74(11):1714-8.  [Content Brief]